Awaiting price reaction for this filing.
Piramal Pharma's US step-down subsidiary Piramal Healthcare Inc. (PHI) will subscribe to 1,903 optionally convertible redeemable preference shares (OCRPS) in PPL Pharma Inc., another wholly owned US step-down subsidiary. The total deal value is USD 190.3 million (about Rs. 1,626 crore), funded partly by USD 40.1 million in cash and mostly by converting an existing USD 150.2 million unsecured loan owed by PPL Pharma to PHI into preference shares. PPL Pharma is a Delaware-incorporated holding entity for Piramal's overseas subsidiaries with a turnover of around USD 4.4 million in 2023. Both PHI and PPL Pharma will continue to remain 100% wholly owned subsidiaries, so there is no change in the parent company's ownership or control.
This is an internal group restructuring and not a fundraise from the market. Existing shareholders are not affected — ownership percentages in the listed entity remain unchanged. The conversion of an inter-company loan into preference shares is largely an accounting/balance sheet exercise and is unlikely to have a direct impact on the stock price.